CN107281179A - A kind of application of polymethoxyflavone on prevention of cardiovascular anti-inflammatory drugs are prepared - Google Patents
A kind of application of polymethoxyflavone on prevention of cardiovascular anti-inflammatory drugs are prepared Download PDFInfo
- Publication number
- CN107281179A CN107281179A CN201710570533.7A CN201710570533A CN107281179A CN 107281179 A CN107281179 A CN 107281179A CN 201710570533 A CN201710570533 A CN 201710570533A CN 107281179 A CN107281179 A CN 107281179A
- Authority
- CN
- China
- Prior art keywords
- flavones
- hydroxyls
- nobiletin
- polymethoxyflavone
- cardiovascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of application of polymethoxyflavone on prevention of cardiovascular anti-inflammatory drugs are prepared.The present invention has found that polymethoxyflavone class compound is obvious to the preventive effect of cardiovascular inflammation, shows that polymethoxyflavone has the application for preparing prevention of cardiovascular anti-inflammatory drugs by cell experiment and zoopery.The present invention can instruct the exploitation of new prevention of cardiovascular inflammation method, and new direction and strategy are provided for the development and application of future studies Nobiletin and related polymethoxyflavone class compound.
Description
Technical field
The present invention relates to the pharmacy application of polymethoxyflavone, and in particular to a kind of polymethoxyflavone is preparing the prevention heart
Application on vascular inflammation medicine.
Background technology
In recent years, either western developed country or China, the Metabolic syndrome such as cardiovascular and cerebrovascular is abnormal, fat and diabetes
Disease incidence is dramatically increased, and has become serious social concern.Result of study is shown, except foreign genetic element, main
Reason is that, as people's living standard is improved and the westernization influence of diet, the high lipid diet of fleshiness progressively instead of our tradition
The east diet based on vegetables and fruits, intake red meat (l-cn), egg and soybean (phosphatidyl choline and choline) or its
It contains the food of trimethylamine substituent.Although it is left-handed that traditional nutrition thinks that red meat, yolk, liver, soybean etc. are rich in
Carnitine, lecithin (phosphatidyl choline), choline etc. are beneficial to the food function factor of health, and in food industry
These three materials are used in large quantities as functional food additives.But, 2011-2013 is published in《New England
Journal of Medicine》、《Nature》With《Nature Medicine》Deng research, first passage animal and human body are real
Test, it was demonstrated that edible l-cn, phosphatidyl choline and choline significantly facilitated angiocardiopathy generation [Wang Z,
Klipfell E,Bennett BJ,Koeth R,Levison BS,DuGar B,Feldstein AE,Britt EB,Fu X,
Chung YM,Wu Y,Schauer P,Smith JD,Allayee H,Tang WH,Didonato JA,Lusis AJ,Hazen
SL.Gut flora metabolism of phosphatidylcholine promotes cardivascular
disease.Nature,2011,472(7341):57-63.]。
Gut flora by l-cn, phosphatidyl choline and choline etc. be converted into trimethylamine (Trimethylamine,
TMA).In liver, TMA is by hapaflavin monooxygenase (FMOs) oxidation generation TMAO (TMAO).Numerous studies have been demonstrate,proved
Real, TMAO is to cause the important independent factor of atherosclerosis, in atherosclerosis crowd's blood, and TMAO level shows
Higher than ordinary person.TMAO is most typical a kind of biomarker in angiocardiopathy patient blood, and it has attack cardiovascular
Cell, the toxic action for inducing the angiocardiopathies such as atherosclerosis.Atherosclerosis will induce coronary disease once occurring
Many cardiovascular and cerebrovascular diseases such as disease, angina pectoris, myocardial infarction and cerebral infarction [Tang WH, Hazen SL.The
contributory role of gut microbiota in cardiovascular disease.J Clin
Invest.2014,124(10):4204-4211.]。
The high lipid diet of fleshiness is to cause the key factor of atherosclerosis, obesity, hyperglycaemia, high fat of blood etc..Heart and brain
Vascular diseases are a kind of common diseases of serious threat human health, and it has, and the incidence of disease is high, disability rate is high, the death rate is high, recurrence
The characteristics of rate is high, complication is more.China's Patients with Cardiovascular/Cerebrovascular Diseases alreadys exceed 2.7 hundred million people, and heart and brain blood is died from the whole world every year
The number of pipe disease occupies the first place of the various causes of the death.
Containing abundant polymethoxyflavone in dried orange peel, one of main active component of dried orange peel, Nobiletin are used as
Attack of the blood fat to target cell can be suppressed；With anticancer functions such as anti-proliferate, anti-rotation shifting and anti-angiogenic rebirths, it may have prevention
Function [Cheng HL, the Hsieh MJ, Yang such as senile dementia, the generation of anti-tampon, reducing blood lipid and suppression atherosclerosis
JS,Lin CW,Lue KH,Lu KH,Yang SF.Nobiletin inhibits human osteosarcoma cells
metastasis by blocking ERK and JNK-mediated MMPs expression.Oncotarget.2016,
doi:10.18632/oncotarget.9106.]。
The content of the invention
Due to the l-cn, lecithin (the phosphatidyl courage that are rich in the regular diets such as red meat, yolk, liver, soybean
Alkali), used these three materials in large quantities as functional food additives in the composition, and food industry such as choline, and
These materials are converted into TMAO, inducing heart vessel inflammatory reaction is eventually developed to as Atherosclerosis in vivo by absorbing
Change, many cardiovascular and cerebrovascular diseases such as coronary heart diseases and angina pectoris, myocardial infarction and cerebral infarction will be induced.It is an object of the invention to
A kind of application of polymethoxyflavone class compound on prevention of cardiovascular anti-inflammatory drugs are prepared is provided.
The purpose of the present invention is achieved through the following technical solutions：
The present invention has found polymethoxyflavone class compound to the pre- of cardiovascular inflammation by cell experiment and zoopery
Anti- effect is obvious.Therefore, polymethoxyflavone can be used for the medicine for preparing prevention of cardiovascular inflammation.
Described polymethoxyflavone includes the flavones of two or more all methoxy substitutions, one of them or one
Methoxyl group more than individual is optionally substituted by a hydroxyl group.It is preferred that, described polymethoxyflavone is yellow for 3,5,6,7,8,3'- hexa methoxies
Ketone, 5,6,7,8,3', 4'- hexa methoxies flavones (Nobiletin, nobiletin, NOB), 3,5,6,7,3', 4'- hexa methoxies
Flavones, 5,6,7,8,4'- pentamethoxyl flavones (tangeretin, tangeretin, TAN), 5,6,7,3', 4'- pentamethoxyl flavones
(sweet orange flavones, sinensetin, SIN), 5,7,8,3', 4'- pentamethoxyls flavones, 3,5,6,7,4'- pentamethoxyl flavones, 5,
7,8,4'- tetramethoxy flavones (tetra-O-methylisoscutellarein), 5,6,7,4'- tetramethoxy flavones (radix scutellariaes
Element, scutellarein, SCU), 5,7,3', 4'- tetramethoxy flavones, 3- hydroxyls -5,6,7,8,3', 4'- hexa methoxy flavones
(natsudaidain, natsudaidai, NAT), 3- hydroxyls -5,6,7,8,4'- pentamethoxyl flavones (3- hydroxyls-tangeretin), 3- hydroxyls
Base -5,6,7,4'- tetramethoxy flavones, 5- hydroxyls -3,6,7,8,3', 4'- hexa methoxy flavones, 5- hydroxyl -3,7,8,3',
4'- pentamethoxyls flavones, 5- hydroxyls -6,7,8,3', 4'- pentamethoxyl flavones (5- demethylnobiletins), 5- hydroxyl -6,7,
8,4'- tetramethoxy flavones (5- demethyls tangeretin), 5- hydroxyls -3,7,3', 4'- tetramethoxy flavones, 5- hydroxyl -7,8,
3', 4'- tetramethoxy flavones, 5- hydroxyls -6,7,3', 4'- tetramethoxy flavones, 7- hydroxyls -3,5,6,8,3', 4'- hexakis-methoxy
Base flavones, 7- hydroxyls -3,5,6,3', 4'- pentamethoxyl flavones, 5,7- hydroxyls -3,6,8,3', 4'- pentamethoxyl flavones, 5- hydroxyls
Base -6,7,8,3', 4'- pentamethoxyl ring flavones, 5,6,7,4'- tetramethoxy flavones, the methoxies of 3'- hydroxyls -5,6,7,8,4'- five
Base flavones (3'- demethylnobiletins), 4'- hydroxyl -5,6,7,8,3'- pentamethoxyls flavones (4'- demethylnobiletins),
In 3', 4'- hydroxyl -5,6,7,8- tetramethoxy flavones (3', 4'- demethylnobiletin) any one, two or more.
It is furthermore preferred that described polymethoxyflavone is 5,6,7,8,3', 4'- hexa methoxy flavones.5,6,7,8,3',
The dosage of 4'- hexa methoxy flavones is preferably per the daily 20mg-1000mg of kg body weight.
The device have the advantages that：China is Orange Producing big country, produce per year 1495.8 ten thousand tons of citrus, year working process
7,500,000 tons or so of citrus, substantial amounts of orange peel is taken as rubbish directly to fill.Containing abundant in the pericarp of the plants such as Rutaceae
Polymethoxyflavone class compound, Nobiletin and other polymethoxyflavone class compounds effectively can prevent TMAO to induce
The cardiovascular inflammation of generation, reduces the generation of cardiovascular inflammation.The present invention can instruct opening for new prevention of cardiovascular inflammation method
Hair, for future studies Nobiletin and related polymethoxyflavone class compound development and application provide new direction with
Strategy.
Brief description of the drawings
Fig. 1 is different disposal group Human umbilical vein endothelial cells HUVECs growth conditions figure.
Fig. 2 is influence result figure of the Nobiletin to Human umbilical vein endothelial cells HUVECs apoptosis.
Fig. 3 is influence result figure of the Nobiletin to Human umbilical vein endothelial cells HUVECs cell cycle distributions.
Fig. 4 is that Nobiletin induces Choline Chloride the HE coloration result figures that SD Rat Cardiovasculars inflammation suppresses.
Embodiment
Following examples are used to further illustrate the present invention, but should not be construed as limiting the invention.If not referring in particular to
It is bright, the conventional meanses that technological means used is well known to those skilled in the art in embodiment.
The Nobiletin of embodiment 1 is to Human umbilical vein endothelial cells HUVECs growth and the influence of cell cycle distribution
The cell cultivated is Human umbilical vein endothelial cells HUVECs, and culture medium is that DMEM culture mediums (contain 100U/mL's
Penicillin and 100 μ g/mL streptomysin, 10% hyclone), cultivation temperature is 37 DEG C, and gas concentration lwevel is 5%.Every
Rise DMEM culture mediums in add 100 μ L respectively containing 0.2mmol, 0.4mmol, 0.6mmol, 0.8mmol, 1.0mmol, 1.2mmol,
The 2%DMSO solution of 1.4mmol, 1.6mmol, 1.8mmol, 2.0mmol Nobiletin.Human umbilical vein endothelial cells HUVECs exists
Cultivated in the DMEM culture mediums of the Nobiletin containing various concentrations after 24h, collect cell, the extinction of different disposal is detected with mtt assay
Value, calculates half lethal concentration.It is computed, Nobiletin is to Human umbilical vein endothelial cells HUVECs half lethal concentration
13.658mmol/L。
It is 2 by concentration to further understand influence that Nobiletin grows to Human umbilical vein endothelial cells HUVECs
×104Individual cell/mL Human umbilical vein endothelial cells HUVECs is seeded in different Tissue Culture Flasks, when cell growth is to accounting for training
After the 70-80% for supporting bottle bottom of bottle area, following different disposal is set：1 liter of HUVECs containing Human umbilical vein endothelial cells culture medium
0.4mmol/L TMAO (TMAO treatment groups) are added in (normal group), 1 liter of HUVECs containing Human umbilical vein endothelial cells culture medium,
0.4mmol/L TMAO and 0.6mmol/L Nobiletins are added in 1 liter of HUVECs containing Human umbilical vein endothelial cells culture medium (low
Concentration Nobiletin treatment group), add in 1 liter of HUVECs containing Human umbilical vein endothelial cells culture medium 0.4mmol/L TMAO and
In 1.0mmol/L Nobiletins (middle concentration Nobiletin treatment group), 1 liter of HUVECs containing Human umbilical vein endothelial cells culture medium
Add 0.4mmol/L TMAO and 1.4mmol/L Nobiletin (high concentration Nobiletin treatment group) (Fig. 1).Do not existed together above-mentioned
After reason culture 24h, cell is collected into centrifuge tube, is washed with the PBS of 4 DEG C of precoolings after cell, 70% ethanol of -20 DEG C of precoolings is added
And mix, 4 DEG C stand overnight after fixed cell, and 1000rpm centrifugations discard ethanol, add appropriate PBS solution, and adjustment cell is close
Spend for (1-2) × 106What individual cell/mL, the final concentration of 50 μ g/mL of addition PI and final concentration of 50g/mL polluted without DNA enzymatic
After RNase, room temperature lucifuge dyeing 30min, flow cytomery Human umbilical vein endothelial cells HUVECs cell cycle and thin
Born of the same parents' apoptosis situation, all experimental results are repeated 3 times, averaged.(Fig. 2,3 table 1,2) show, TMAO can to experimental result
Reduce percentage, increase S phase cell percentages, non-viable non-apoptotic cell and the apoptosis middle and advanced stage cell percentages shared by G1 phase cells
Dramatically increase；Only addition TMAO cell is compared, after addition Nobiletin, the Human umbilical vein endothelial cells HUVECs cultivated
In, G1 phase cells percentage increase, S phases proportion is reduced, and is reduced Apoptosis ratio, with reference to MTT experiment result, is said
Bright TMAO can result in Human umbilical vein endothelial cells HUVECs the S phases retardance and cause Apoptosis, and Nobiletin can
Reduce the influence of the cell cycle caused by TMAO, apoptotic effects of the reduction TMAO to cell.
Influence of the Nobiletin of table 1 processing to HUVECs Apoptosis
| Group | Non-viable non-apoptotic cell/% | Apoptosis middle and advanced stage cell/% | Normal cell/% | Apoptosis early stage cell/% |
| Normal group | 2.64±0.66A | 2.67±0.80A | 92.55±1.80A | 2.13±0.45a |
| TMAO treatment groups | 7.59±2.26B | 29.40±2.96b | 57.14±1.61B | 5.87±2.33b |
| Low concentration Nobiletin treatment group | 5.27±1.96AB | 21.00±1.89c | 66.65±0.97C | 6.41±1.35b |
| Middle concentration Nobiletin treatment group | 5.31±0.6AB | 12.99±1.28d | 75.24±0.75D | 6.47±1.29b |
| High concentration Nobiletin treatment group | 5.34±0.96AB | 7.33±0.68A | 83.58±0.86E | 3.75±0.54ab |
Remarks：Same row difference lowercase, represents there is significant difference in P=0.01 levels；Same row difference capitalization
Letter, represents there is significant difference in P=0.05 levels.
Influence of the Nobiletin of table 2 processing to the HUVECs cell cycles
| Group | G1/% | S/% | G2/% |
| Normal group | 80.00±1.27A | 8.5±0.09A | 11.49±1.37AbB |
| TMAO treatment groups | 58.89±1.15B | 18.71±0.28b | 22.41±1.41a |
| Low concentration Nobiletin treatment group | 63.29±0.44C | 16.20±0.15C | 20.51±0.51a |
| Middle concentration Nobiletin treatment group | 72.31±0.40D | 18.46±0.11b | 9.23±0.29Ab |
| High concentration Nobiletin treatment group | 77.18±0.63E | 9.46±0.16D | 13.36±0.51B |
The Nobiletin of embodiment 2 induces Choline Chloride the influence of SD Rat Cardiovascular inflammation
Experiment SD rats are divided into 5 groups, blank group, control treatment group, low dosage Nobiletin treatment group, middle dosage river are old
Skin element treatment group, high dose Nobiletin treatment group, every group 8.Control treatment group, low dosage Nobiletin treatment group, in
Choline Chloride (the blank of mass concentration 3% is added in dosage Nobiletin treatment group, the drinking-water of high dose Nobiletin treatment group
Choline Chloride is not added with the drinking-water of group), and in daily same time, difference gavage 0.4mL corn oil (blank group, control treatment
Group), the 0.4mL corn oil (low dosage Nobiletin treatment group), the 0.4mL that contain per kg body weight 100mg Nobiletins contain every thousand
Corn oil (middle dosage Nobiletin treatment group), the 0.4mL of gram body weight 200mg Nobiletins contain old per kg body weight 400mg rivers
Pi Su corn oil (high dose Nobiletin treatment group), in the week of continuous gavage 6, after last time gavage terminates, stops diet
Rat is put to death after 12h, heart extracting blood simultaneously collects liver, spleen, kidney and sustainer.Using GAPDH as internal reference, quantitative fluorescent PCR
Inflammatory factor TNF-α, IL-1 β, IL-6 and MCP-1 expression quantity in method detection each group rat blood serum, to sustainer and liver
Carry out HE dyeing detections.Fluorescence quantitative PCR detection result (table 3) shows, under the induction of Choline Chloride, inflammatory factor TNF-α,
IL-1 β, IL-6 and MCP-1 expression are lowered, and Nobiletin processing can mitigate the downward degree of these inflammatory Cytokines Expressions.
The HE dyeing testing results (Fig. 4) of sustainer show that rat aorta inner membrance is slightly thickened after Choline Chloride processing, local grand
Rise, aorta inner skin layer, which has, slightly to be come off, and aorta wall smooth muscle is thickened, middle film elastic fiber hyperplasia, subintima and middle film
It can be seen that vacuole sample is denatured, outer membrane no abnormality seen；After being handled through Nobiletin, aortic tunica intima is complete, middle film smooth muscle cell row
Row are neat, have no smooth muscle cell proliferation, outer membrane no abnormality seen.Illustrate that Nobiletin can suppress the heart caused by Choline Chloride
The inflammatory reaction of vascular tissue.The testing result of liver organization shows that Choline Chloride can result in hepatic portion top layer liver cell
Form visible few around vacuole, liver cell spotty necrosis, liver cell nuclear circle, oval, the increase of part core, portal area and vein
Measure neutrophil infiltration；And after Nobiletin processing, the pathological state of liver organization is eased.Result above shows,
Nobiletin has the cardiovascular inflammation reaction suppressed caused by Choline Chloride.
RT-PCR testing result of the Nobiletin of table 3 processing to cardiovascular region inflammatory Cytokines Expression
| TNF-a | IL1-b | IL-6 | MCP-1 | |
| Control group | 0.32±0.11A | 0.83±0.03a | 0.41±0.14A | 0.59±0.13A |
| High dose group | 1.23±0.12B | 0.94±0.10b | 1.060.03b | 1.35±0.14B |
| Middle dose group | 1.14±0.06B | 0.79±0.25a | 0.62±0.02c | 0.69±0.21A |
| Low dose group | 0.34±0.09A | 0.67±0.02a | 0.38±0.01A | 0.45±0.11A |
The Nobiletin of embodiment 3 is evaluated SD rats bio-toxicity
The liver,spleen,kidney weight that rat is put to death in embodiment 2 is weighed, organ weight ratio is calculated respectively.By in embodiment 2
The blood gathered, room temperature is placed after 1h, and 4 DEG C of 3000rpm centrifuge 10min, collect serum, are detected with automatic clinical chemistry analyzer
Liver function biochemical index：Aspartic acid transaminase (aspartate aminotransferase, AST), alanine aminotransferase
(alanine aminotransferase, ALT), triglyceride (triglyceride, TG) and T-CHOL (total
Cholesterol, T-cho), experimental result is shown in Table 4.From experimental result as can be seen that poor in the absence of conspicuousness between each group of data
Different, Nobiletin does not show bio-toxicity to SD rats.
Bio-toxicity evaluation of the Nobiletin of table 4 to SD rats
Above-described embodiment is preferably embodiment, but embodiments of the present invention are not by above-described embodiment of the invention
Limitation, other any Spirit Essences without departing from the present invention and the change made under principle, modification, replacement, combine, simplification,
Equivalent substitute mode is should be, is included within protection scope of the present invention.
Claims (4)
1. a kind of application of polymethoxyflavone on prevention of cardiovascular anti-inflammatory drugs are prepared.
2. application according to claim 1, it is characterised in that：Described polymethoxyflavone is 3,5,6,7,8,3'- six
Methoxy flavone, 5,6,7,8,3', 4'- hexa methoxies flavones, 3,5,6,7,3', 4'- hexa methoxies flavones, 5,6,7,8,4'-
Pentamethoxyl flavones, 5,6,7,3', 4'- pentamethoxyls flavones, 5,7,8,3', 4'- pentamethoxyls flavones, 3,5,6,7,4'- five
Methoxy flavone, 5,7,8,4'- tetramethoxy flavones, 5,6,7,4'- tetramethoxy flavones, 5,7,3', 4'- tetramethoxies are yellow
Ketone, 3- hydroxyls -5,6,7,8,3', 4'- hexa methoxy flavones, 3- hydroxyl -5,6,7,8,4'- pentamethoxyls flavones, 3- hydroxyl -5,
6,7,4'- tetramethoxy flavones, 5- hydroxyls -3,6,7,8,3', 4'- hexa methoxy flavones, the first of 5- hydroxyls -3,7,8,3', 4'- five
Epoxide flavones, 5- hydroxyls -6,7,8,3', 4'- pentamethoxyl flavones, 5- hydroxyl -6,7,8,4'- tetramethoxy flavones, 5- hydroxyls -
3,7,3', 4'- tetramethoxy flavones, 5- hydroxyls -7,8,3', 4'- tetramethoxy flavones, the methoxy of 5- hydroxyls -6,7,3', 4'- tetra-
Base flavones, 7- hydroxyls -3,5,6,8,3', 4'- hexa methoxy flavones, 7- hydroxyls -3,5,6,3', 4'- pentamethoxyl flavones, 5,7-
Hydroxyl -3,6,8,3', 4'- pentamethoxyl flavones, 5- hydroxyls -6,7,8,3', 4'- pentamethoxyl ring flavones, 5,6,7,4'- tetramethyls
Epoxide flavones, 3'- hydroxyl -5,6,7,8,4'- pentamethoxyls flavones, 4'- hydroxyl -5,6,7,8,3'- pentamethoxyls flavones, 3',
In 4'- hydroxyl -5,6,7,8- tetramethoxy flavones any one, two or more.
3. application according to claim 1 or 2, it is characterised in that：Described polymethoxyflavone is 5,6,7,8,3',
4'- hexa methoxy flavones.
4. application according to claim 3, it is characterised in that：Described 5,6,7,8,3', 4'- hexa methoxy flavones makes
It is per the daily 20-1000 mg of kg body weight with dosage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710570533.7A CN107281179A (en) | 2017-07-13 | 2017-07-13 | A kind of application of polymethoxyflavone on prevention of cardiovascular anti-inflammatory drugs are prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710570533.7A CN107281179A (en) | 2017-07-13 | 2017-07-13 | A kind of application of polymethoxyflavone on prevention of cardiovascular anti-inflammatory drugs are prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107281179A true CN107281179A (en) | 2017-10-24 |
Family
ID=60100804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710570533.7A Withdrawn CN107281179A (en) | 2017-07-13 | 2017-07-13 | A kind of application of polymethoxyflavone on prevention of cardiovascular anti-inflammatory drugs are prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107281179A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109464437A (en) * | 2018-12-24 | 2019-03-15 | 华中科技大学同济医学院附属协和医院 | Purposes of the Nobiletin in treatment aortic valve calcification disease |
| CN115197191A (en) * | 2021-04-09 | 2022-10-18 | 中国海洋大学 | Novel traditional Chinese medicine flavone derivative and preparation method and application thereof |
| CN115197190A (en) * | 2021-04-09 | 2022-10-18 | 中国海洋大学 | Novel plant flavone derivative and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015006863A1 (en) * | 2013-07-16 | 2015-01-22 | Vasudevan Harish | Method of extracting flavonoids and/or polyphenols from dried and powdered orange peels, compositions therefrom, and methods of treatment of diseases associated with chronic inflammation |
| JP2017079712A (en) * | 2015-10-27 | 2017-05-18 | 株式会社ホソダＳｈｃ | Krill oil composition |
-
2017
- 2017-07-13 CN CN201710570533.7A patent/CN107281179A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015006863A1 (en) * | 2013-07-16 | 2015-01-22 | Vasudevan Harish | Method of extracting flavonoids and/or polyphenols from dried and powdered orange peels, compositions therefrom, and methods of treatment of diseases associated with chronic inflammation |
| JP2017079712A (en) * | 2015-10-27 | 2017-05-18 | 株式会社ホソダＳｈｃ | Krill oil composition |
Non-Patent Citations (1)
| Title |
|---|
| 宫先卫: "《硕士学位论文》", 23 May 2011 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109464437A (en) * | 2018-12-24 | 2019-03-15 | 华中科技大学同济医学院附属协和医院 | Purposes of the Nobiletin in treatment aortic valve calcification disease |
| CN109464437B (en) * | 2018-12-24 | 2020-11-10 | 华中科技大学同济医学院附属协和医院 | Application of nobiletin in treating aortic valve calcification disease |
| CN115197191A (en) * | 2021-04-09 | 2022-10-18 | 中国海洋大学 | Novel traditional Chinese medicine flavone derivative and preparation method and application thereof |
| CN115197190A (en) * | 2021-04-09 | 2022-10-18 | 中国海洋大学 | Novel plant flavone derivative and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Plamada et al. | Polyphenols—Gut microbiota interrelationship: A transition to a new generation of prebiotics | |
| Wang et al. | Inhibition of LPS-induced oxidative damages and potential anti-inflammatory effects of Phyllanthus emblica extract via down-regulating NF-κB, COX-2, and iNOS in RAW 264.7 cells | |
| Wu et al. | Diverse phytochemicals and bioactivities in the ancient fruit and modern functional food pomegranate (Punica granatum) | |
| Cannataro et al. | Polyphenols in the Mediterranean diet: From dietary sources to microRNA modulation | |
| Todorova et al. | Plant adaptogens—History and future perspectives | |
| Krga et al. | Anthocyanins: From sources and bioavailability to cardiovascular-health benefits and molecular mechanisms of action | |
| Yin et al. | Gut microbiota, dietary phytochemicals, and benefits to human health | |
| Covas et al. | The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial | |
| Pan et al. | Regulatory effect of Grifola frondosa extract rich in polysaccharides and organic acids on glycolipid metabolism and gut microbiota in rats | |
| Guo et al. | Inhibitory effects of fermented Ougan (Citrus reticulata cv. Suavissima) juice on high-fat diet-induced obesity associated with white adipose tissue browning and gut microbiota modulation in mice | |
| Yang et al. | Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis | |
| Luo et al. | Development of obesity is reduced in high-fat fed mice fed whole raspberries, raspberry juice concentrate, and a combination of the raspberry phytochemicals ellagic acid and raspberry ketone | |
| Ionescu et al. | Dietary phytoestrogens and their metabolites as epigenetic modulators with impact on human health | |
| Zhou et al. | Geographical variations of triterpenoid contents in Cyclocarya paliurus leaves and their inhibitory effects on HeLa cells | |
| Dokkaew et al. | Protective effects of defatted sticky rice bran extracts on the early stages of hepatocarcinogenesis in rats | |
| CN107281179A (en) | A kind of application of polymethoxyflavone on prevention of cardiovascular anti-inflammatory drugs are prepared | |
| Luo et al. | Interactions between gut microbiota and polyphenols: new insights into the treatment of fatigue | |
| Mao et al. | Costunolide protects against alcohol‐induced liver injury by regulating gut microbiota, oxidative stress and attenuating inflammation in vivo and in vitro | |
| Owczarek et al. | The impact of dietary polyphenols on COX-2 expression in colorectal cancer | |
| Jeong et al. | Anti-obesity effect of Dioscorea oppositifolia extract in high-fat diet-induced obese mice and its chemical characterization | |
| Yusni et al. | Action mechanism of Rosella (Hibiscus sabdariffa L.) used to treat metabolic syndrome in elderly women | |
| Jung et al. | Mulberry (Morus alba L.) fruit extract ameliorates inflammation via regulating microRNA-21/132/143 expression and increases the skeletal muscle mitochondrial content and AMPK/SIRT activities | |
| Park et al. | Rice bran fermented with kimchi-derived lactic acid bacteria prevents metabolic complications in mice on a high-fat and-cholesterol diet | |
| Centner et al. | The role of phytochemicals and gut microbiome in atherosclerosis in preclinical mouse models | |
| Luo et al. | Astragaloside IV ameliorates fat metabolism in the liver of ageing mice through targeting mitochondrial activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20171024 |
|
| WW01 | Invention patent application withdrawn after publication |